Clinical Trial Update: Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the aldosterone synthase inhibitor LCI699 in primary aldosteronism has completed, providing proof-of-concept for this mechanism.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aldosteronism

Drugs mentioned

• LCI699 (LCI699)

Snippet

Sponsor: Novartis | Conditions: Primary Hyperaldosteronism | Phase 2 | Status: COMPLETED